...NuView granted Otsuka exclusive, worldwide rights to develop and commercialize NuView's genomic-based vasoactive intestinal peptide receptor...
...applications. Otsuka will provide funding for all future clinical trials and commercialization, and will use NuView's...
...Phase I trial "in the coming months." The partners could not be reached for details. NuView...

...Calif.) that has CE Mark approval in the EU and 510(k) clearance in the U.S. NuView Life Sciences Inc....

...vasoactive intestinal peptide receptor 1 (VPAC1) on prostate cancer cells. Further details were not disclosed. NuView Life Sciences Inc....

...over expressed in all breast cancers. Data were published in the Journal of Nuclear Medicine. NuView Life Sciences Inc....

...in preclinical testing to image the heart and blood flow. Financial terms were not disclosed. NuView...